Our findings identified UBE2T/RNF8-H2AX-CHK1 as a novel pathway of DDR and HCC radioresistance, highlighting the prospect and merit of disrupting this pathway to develop adjuvant treatments for HCC RT. This evidence concerns the gene H2AX and hepatocellular carcinoma.